1. Home
  2. SINT vs AKTX Comparison

SINT vs AKTX Comparison

Compare SINT & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SiNtx Technologies Inc.

SINT

SiNtx Technologies Inc.

HOLD

Current Price

$3.98

Market Cap

15.0M

Sector

Health Care

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.34

Market Cap

14.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SINT
AKTX
Founded
1996
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.0M
14.4M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
SINT
AKTX
Price
$3.98
$0.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$25.00
$3.30
AVG Volume (30 Days)
80.0K
1.0M
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,270,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$80.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.71
$0.29
52 Week High
$7.36
$1.73

Technical Indicators

Market Signals
Indicator
SINT
AKTX
Relative Strength Index (RSI) 59.65 29.30
Support Level $3.30 $0.29
Resistance Level $4.23 $0.36
Average True Range (ATR) 0.34 0.07
MACD 0.09 -0.00
Stochastic Oscillator 80.88 15.84

Price Performance

Historical Comparison
SINT
AKTX

About SINT SiNtx Technologies Inc.

SINTX Technologies Inc is a ceramics company, focused on providing solutions in a variety of biomedical, technical, and antipathogenic applications. It has grown from focusing on the research, development, and commercialization of medical devices manufactured with silicon nitride to becoming a renowed ceramics company engaged in diverse fields, including biomedical, technical, and antipathogenic applications. Its biomedical products are biocompatible, bioactive, antipathogenic, and to have good bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans in the US, Europe, Brazil, and Taiwan.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: